×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
NASDAQ:EVAX

Evaxion Biotech A/S News Headlines

$2.23
+0.26 (+13.20%)
(As of 07/5/2022 05:45 PM ET)
Add
Compare
Today's Range
$2.00
▼
$2.39
50-Day Range
$1.60
▼
$3.05
52-Week Range
$1.51
▼
$25.04
Volume
85,106 shs
Average Volume
228,098 shs
Market Capitalization
$51.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Get Evaxion Biotech A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

EVAX Media Mentions By Week

EVAX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EVAX
News Sentiment
▼
0.94

0.80
▲
Average
Medical
News Sentiment

EVAX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EVAX Articles
This Week
▼
2

0
▲
EVAX Articles
Average Week



EVAX Stock News Headlines Today

SourceHeadline
finance.yahoo.com logoEvaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
finance.yahoo.com - June 30 at 8:45 AM
finance.yahoo.com logoEvaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung Cancer
finance.yahoo.com - June 23 at 3:40 PM
finance.yahoo.com logoEvaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
finance.yahoo.com - June 23 at 9:53 AM
finance.yahoo.com logoEvaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital
finance.yahoo.com - June 7 at 8:20 AM
seekingalpha.com logoEvaxion Biotech files offering to sell up to $100M ordinary shares
seekingalpha.com - May 20 at 6:17 PM
seekingalpha.com logoEvaxion Biotech A/S' (EVAX) CEO Lars Wegner on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 2:32 PM
investing.com logoEvaxion Biotech Tops Q1 EPS by 8c
investing.com - May 11 at 9:32 AM
benzinga.com logoEvaxion Biotech: Q1 Earnings Insights
benzinga.com - May 11 at 9:32 AM
finance.yahoo.com logoEvaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 9:32 AM
seekingalpha.com logoDanish biotech, Evaxion surges after production update on personalized cancer candidate
seekingalpha.com - May 10 at 9:50 AM
finance.yahoo.com logoEvaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02
finance.yahoo.com - May 10 at 9:50 AM
benzinga.com logoEvaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
benzinga.com - April 28 at 3:19 PM
finance.yahoo.com logoEvaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies
finance.yahoo.com - April 6 at 12:19 PM
finance.yahoo.com logoEvaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
finance.yahoo.com - March 22 at 7:31 AM
seekingalpha.com logoEvaxion Biotech appoints Karmark as CFO, Nissen as COO
seekingalpha.com - March 14 at 8:54 AM
finance.yahoo.com logoEvaxion Biotech Strengthens Management Team with Two Senior Appointments
finance.yahoo.com - March 14 at 8:54 AM
finance.yahoo.com logoEvaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
finance.yahoo.com - January 26 at 8:30 AM
finance.yahoo.com logoEvaxion Biotech AS Sponsored ADR (EVAX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
finance.yahoo.com - January 25 at 3:28 PM
finance.yahoo.com logoEvaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma
finance.yahoo.com - January 18 at 10:01 AM
finance.yahoo.com logoDo Options Traders Know Something About Evaxion (EVAX) Stock We Don't?
finance.yahoo.com - December 29 at 3:08 PM
finance.yahoo.com logoEvaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - November 9 at 9:16 PM
finance.yahoo.com logoEvaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update
finance.yahoo.com - November 9 at 11:15 AM
finanznachrichten.de logoEvaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA (pembrolizumab) in Patients with Melanoma
finanznachrichten.de - November 5 at 7:54 AM
finance.yahoo.com logoEvaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
finance.yahoo.com - November 5 at 7:54 AM
marketwatch.com logoEvaxion Biotech Shares Double in Heavier-Than-Normal Trade
marketwatch.com - November 4 at 4:18 PM
nasdaq.com logoWhat Is The Ownership Structure Like For Evaxion Biotech A/S (NASDAQ:EVAX)?
nasdaq.com - November 2 at 8:19 AM
finance.yahoo.com logoIs Evaxion Biotech A/S (NASDAQ:EVAX) Popular Amongst Insiders?
finance.yahoo.com - November 1 at 10:31 AM
finance.yahoo.com logoEvaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital
finance.yahoo.com - October 26 at 9:32 AM
markets.businessinsider.com logoEvaxion Announces Collaboration With Merck & Co. To Evaluate EVX-01 With KEYTRUDA
markets.businessinsider.com - October 25 at 8:22 AM
finance.yahoo.com logoEvaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
finance.yahoo.com - October 25 at 8:22 AM
finance.yahoo.com logoEvaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award
finance.yahoo.com - October 14 at 8:08 AM
finance.yahoo.com logoEvaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021
finance.yahoo.com - October 12 at 5:48 PM
finance.yahoo.com logoEvaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer
finance.yahoo.com - September 21 at 9:33 AM
barrons.com logoEvaxion Biotech A/S ADR
barrons.com - August 26 at 11:23 PM
finance.yahoo.com logoEvaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update
finance.yahoo.com - August 12 at 6:18 PM
markets.businessinsider.com logoHere's what to expect from Globus Medical A's earnings report
markets.businessinsider.com - August 4 at 10:23 AM
finance.yahoo.com logoEvaxion Biotech (NASDAQ:EVAX) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - August 3 at 1:16 PM
finance.yahoo.com logoEvaxion's Cancer Immunotherapy Shows Antitumor Effect In Early-Stage Melanoma Study
finance.yahoo.com - July 8 at 2:25 PM
msn.com logoThe Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
msn.com - July 8 at 9:22 AM
marketwatch.com logoEvaxion Cancer-Treatment Studies Progress
marketwatch.com - July 8 at 9:22 AM
finance.yahoo.com logoEvaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02
finance.yahoo.com - July 8 at 9:22 AM
finance.yahoo.com logoIs Evaxion Biotech A/S (EVAX) A Good Stock To Buy?
finance.yahoo.com - June 15 at 2:29 PM
marketwatch.com logoEvaxion Biotech Sees Positive Data in Covid-19 Vaccine Program
marketwatch.com - June 3 at 2:07 PM
markets.businessinsider.com logoEvaxion Biotech Aims To Develop Next Generation Of Corona Virus Vaccines
markets.businessinsider.com - June 3 at 9:07 AM
finance.yahoo.com logoEvaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine
finance.yahoo.com - June 3 at 9:07 AM
finance.yahoo.com logoEvaxion Biotech Appoints Lars Holtug to the Board of Directors
finance.yahoo.com - May 26 at 9:45 AM
finance.yahoo.com logoEvaxion Biotech A/S - ADR to Host Earnings Call
finance.yahoo.com - May 13 at 8:02 AM
nasdaq.com logoDo Institutions Own Evaxion Biotech A/S (NASDAQ:EVAX) Shares?
nasdaq.com - May 6 at 8:54 AM
finance.yahoo.com logoEvaxion Biotech to Host Q1 2021 Corporate Update Conference Call & Webcast on May 13
finance.yahoo.com - May 6 at 8:54 AM
finance.yahoo.com logoWhat Kind Of Investors Own Most Of Evaxion Biotech A/S (NASDAQ:EVAX)?
finance.yahoo.com - May 5 at 12:52 PM
Get Evaxion Biotech A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:EVAX) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.